Patent ID: 11913078
Assignee: MYRIAD INTERNATIONAL GMBH
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 10:
11. A method of classifying an estrogen receptor positive and HER2 negative breast tumor from a patient, the method comprising:
(a) extracting RNA from a sample from the tumor from the patient;
(b) amplifying a set of marker genes in the RNA, the set of marker genes comprising AURKA and at least two of the following genes: BIRC5, PVALB, NMU, STC2, RBBP8, PTGER3, CXCL12, CDH1, and PIP;
(c) determining the RNA expression levels of the set of marker genes;
(d) analyzing the expression levels of the set of marker genes by combining the expression levels to yield a test combined score; and
(e) classifying the tumor as responsive to a cytotoxic chemotherapy if the test combined score exceeds a reference combined score, or classifying the tumor as non-responsive to a cytotoxic therapy if the test combined score does not exceed the reference combined score.